Last update :
08/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Topotecan  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Acumil Mexico
Camtoop Mexico
Cantop India
Hycamtin Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Ecuador, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Malaysia, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United States of America, Venezuela
Oncotecan Colombia, Ecuador
Potactasol Argentina, Belgium, Germany, Norway, Romania
Tekan L Turkey
Topodria Colombia
Topokebir Argentina, Peru
Toposec Peru
Topotecan Belgium, Canada, Colombia, Germany, Great Britain, Norway, Peru, Romania, Spain
Topotel Egypt
Toranex Mexico
Tpopoxin Turkey
Viatopin Hungary
Stability of mixtures   Injection   Stability of mixtures : Topotecan     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Glucose 5% 0,05 mg/ml
Injection   Topotecan   
Injection   Palonosetron hydrochloride 25 µg/ml
20°C-25°C
4 Hour
Not specified 1976
Level of evidence A+
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Carboplatin 0,45 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Cimetidine hydrochloride 2,88 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Cisplatin 0,084 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Cyclophosphamide 10 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Doxorubicin hydrochloride 1 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Etoposide 0,2 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Granisetron hydrochloride 0,01 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Ifosfamide 7,14 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Methylprednisolone sodium succinate 1,2 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Metoclopramide hydrochloride 0,86 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Ondansetron hydrochloride 0,24 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Paclitaxel 0,27 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Prochlorperazine edysilate 0,096 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified NaCl 0,9% or Glucose 5% 0,028 mg/ml
Injection   Topotecan   
Injection   Vincristine sulfate 0,5 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
  Mentions Légales